Cargando…

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria

BACKGROUND: Chronic spontaneous urticaria (CSU) negatively impacts patients' sleep, thereby reducing health‐related quality of life (HRQoL). Half of patients with inadequately controlled CSU report sleep interference often or every night, which can lead to depression, anxiety, social, and work‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giménez‐Arnau, Ana, Maurer, Marcus, Bernstein, Jonathan, Staubach, Petra, Barbier, Nathalie, Hua, Eva, Severin, Thomas, Joubert, Yolandi, Janocha, Reinhold, Balp, Maria‐Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848195/ https://www.ncbi.nlm.nih.gov/pubmed/35218324 http://dx.doi.org/10.1002/clt2.12121

Ejemplares similares

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()
por: Metz, Martin, et al.
Publicado: (2022)

Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
por: Bernstein, Jonathan A., et al.
Publicado: (2023)

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System
por: Ji, Yan, et al.
Publicado: (2023)

Ligelizumab treatment for severe asthma: learnings from the clinical development programme
por: Trischler, Jordis, et al.
Publicado: (2021)

ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
por: Weller, Karsten, et al.
Publicado: (2015)

The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE‐CSU
por: Maurer, M., et al.
Publicado: (2017)

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
por: Casale, Thomas B., et al.
Publicado: (2023)

The rationale for development of ligelizumab in food allergy
por: Wood, Robert A., et al.
Publicado: (2022)

Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review
por: Balp, Maria-Magdalena, et al.
Publicado: (2021)

Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey
por: Krause, Karoline, et al.
Publicado: (2023)

Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria
por: Kolkhir, Pavel, et al.
Publicado: (2021)

The Burden of Chronic Urticaria from Brazilian Patients’ Perspective
por: Balp, Maria-Magdalena, et al.
Publicado: (2017)

In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria
por: Moñino‐Romero, Sherezade, et al.
Publicado: (2023)

Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
por: Gimenéz-Arnau, Ana M., et al.
Publicado: (2016)

Sleep Disturbance in Patients with Urticaria and Atopic Dermatitis: An Underestimated Burden
por: MANN, Caroline, et al.
Publicado: (2020)

Erratum to: The Burden of Chronic Urticaria from Brazilian Patients’ Perspective
por: Balp, Maria-Magdalena, et al.
Publicado: (2017)

EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria
por: Hawe, Emma, et al.
Publicado: (2016)

The Expression of IL-17, in Chronic Spontaneous Urticaria Is Linked to Semaphorin5A
por: Lobna, Matanis, et al.
Publicado: (2021)

Burden of chronic urticaria relative to psoriasis in five European countries
por: Balp, M.M., et al.
Publicado: (2017)

Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
por: Finlay, A.Y., et al.
Publicado: (2017)

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence
por: Metz, Martin, et al.
Publicado: (2020)

Definition of Recurrent Chronic Spontaneous Urticaria
por: MELÉ-NINOT, Gemma, et al.
Publicado: (2020)

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria
por: Graham, Jonathan, et al.
Publicado: (2016)

IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms
por: Kuo, Be-Sheng, et al.
Publicado: (2022)

Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE‐CSU
por: Sussman, G., et al.
Publicado: (2018)

Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling
por: Stull, Donald E., et al.
Publicado: (2016)

H(1)-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects – A Retrospective Survey Study
por: Weller, Karsten, et al.
Publicado: (2011)

Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data
por: Staubach, P., et al.
Publicado: (2017)

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin
por: Metz, Martin, et al.
Publicado: (2017)

In silico Identification of Immune Cell-Types and Pathways Involved in Chronic Spontaneous Urticaria
por: Prosty, Connor, et al.
Publicado: (2022)

The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
por: Gasser, Pascal, et al.
Publicado: (2020)

Basophil Activation Test identifies the patients with Chronic Spontaneous Urticaria suffering the most active disease
por: Curto‐Barredo, Laia, et al.
Publicado: (2016)

The Impact of Chronic Urticaria from the Patient’s Perspective: A Survey in Five European Countries
por: Balp, Maria-Magdalena, et al.
Publicado: (2015)

Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
por: Metz, Martin, et al.
Publicado: (2021)

Pathobiology of Second-Generation Antihistamines Related to Sleep in Urticaria Patients
por: Mann, Caroline, et al.
Publicado: (2022)

Hyperresponsiveness to antihistamines in spontaneous urticaria and heat urticaria
por: Durda, J., et al.
Publicado: (2017)

Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
por: Williams, Paul V., et al.
Publicado: (2018)

Economic burden of refractory chronic spontaneous urticaria on Kuwait’s health system
por: Al-Ahmad, Mona, et al.
Publicado: (2016)

Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both
por: Chen, Yudi, et al.
Publicado: (2021)

Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
por: Metz, Martin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m8cfprcc4q6h4qtt73oe9kgmc8